摘要
目的 观察重组人单核细胞趋化蛋白 1(MCP 1)在骨肉瘤化疗过程中的作用。方法 建立裸鼠荷人骨肉瘤动物模型。分别及联合应用重组人MCP 1和高剂量氨甲喋呤 (HD MTX)对其进行治疗 ,并设立空白对照。观察瘤体的生长及病理指标。结果 MCP 1可抑制骨肉瘤体的生长 ,但效果不理想 ;HD MTX可明显抑制骨肉瘤体的生长 ,效果显著 ,但可出现肿瘤再生长 ;MCP 1可增强HD MTX对瘤体的抑制作用 ,且能明显延迟肿瘤再生长的时间。结论 重组人MCP 1在骨肉瘤进行HD
Objective To observe the effect of human recombinant Monocyte Chemoattractant Protein-1 (MCP-1) during the course of chemotherapy for osteosarcoma. Methods The animal model of human osteosarcoma was established in nude mice. They were given high doses of methotrexate (HD-MTX) or human recombinant MCP-1 alone or combined, and a blank control group was set up. Observations on the growth and pathologic markers of xenotransplanted osteosarcoma were observed and pathological examinations were made. Results MCP-1 inhibited the growth of osteosarcoma, but its effectiveness was not ideal. HD-MTX could inhibit significantly the growth of osteosarcoma, but the tumors could regrow. MCP-1 not only could enhance the tumor inhibition of HD-MTX, but also retard the regrowth of the tumors. Conclusion Recombinant human MCP-1 can enhance significantly the therapeutic effect of HD-MTX on osteosarcoma.
出处
《上海医学》
CAS
CSCD
北大核心
2004年第9期674-676,i002,共4页
Shanghai Medical Journal
基金
福建省青年科技人才创新项目